Seroatlas · Human Serome Atlas

IFITM5

Interferon-induced transmembrane protein 5

Also known as: BRIL, DSPA1, fragilis4, Hrmp1, IFM5_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
A6NNB3
Gene
IFITM5
Ensembl
ENSG00000206013
Chromosome
11
Canonical length
132 aa
Protein class
Disease related genes, Human disease related genes, Predicted membrane proteins
Subcellular location
Vesicles,Plasma membrane,Cytosol

OverviewNCBI Gene

This gene encodes a membrane protein thought to play a role in bone mineralization. This gene is located on chromosome 11 in a cluster of related genes which are induced by interferon, however, this gene has not been shown to be interferon inducible. A similar gene, located in a gene cluster on mouse chromosome 7, is a member of the interferon-inducible fragilis gene family. The mouse gene encodes a transmembrane protein described as participating in germ cell competence. A mutation in the 5' UTR of this gene has been associated with osteogenesis imperfecta type V (PMID: 22863190, 22863195). [provided by RefSeq, Aug 2012]

Canonical amino-acid sequenceUniProt

132 residues, UniProt reviewed canonical sequence.

>A6NNB3|IFITM5
     1  MDTAYPREDT RAPTPSKAGA HTALTLGAPH PPPRDHLIWS VFSTLYLNLC CLGFLALAYS
    61  IKARDQKVVG DLEAARRFGS KAKCYNILAA MWTLVPPLLL LGLVVTGALH LARLAKDSAA
   121  FFSTKFDDAD YD

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IFITM5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
2
Mean surface accessibility (rSASA)
0.54
Highest tissue expression
6.9 nTPM

Expression across tissuesHPA

Tissue

  • pancreas: 6.9 nTPM
  • bone marrow: 0.7 nTPM
  • kidney: 0.6 nTPM
  • lung: 0.4 nTPM
  • small intestine: 0.3 nTPM
  • breast: 0.2 nTPM

Single-cell type

  • innate lymphoid cells: 0.3 nCPM
  • b-cells: 0.2 nCPM
  • decidual stromal cells: 0.1 nCPM
  • endometrial stromal cells: 0.1 nCPM
  • epididymal efferent duct absorptive cells: 0.1 nCPM
  • epididymal principal cells: 0.1 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • cerebral cortex: 11 nTPM
  • pons: 1.6 nTPM
  • thalamus: 0.7 nTPM
  • medulla oblongata: 0.6 nTPM
  • midbrain: 0.6 nTPM
  • amygdala: 0.5 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about IFITM5.

Disease | AllUniProt

Conditions IFITM5 is implicated in, by any mechanism.

Disease | GeneticClinVar

2 pathogenic / likely-pathogenic of 181 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Osteogenesis imperfecta type 5
  • IFITM5-related disorder

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.95
gnomAD pLI
0
gnomAD missense Z
-0.67
DepMap mean gene effect
-0.06
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of IFITM5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IFITM5 as an antibody target. Whether an autoantibody or antibody against IFITM5 could matter depends on whether native IFITM5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IFITM5 is annotated at the cell surface, where native IFITM5 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label IFITM5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/IFITM5. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...